Stock Taper Fourth Quarter Revenue: $384.8 million, up from $370.7 million in Q4 2024.
Full Year Revenue: $1.46 billion, down from $1.50 billion in 2024.
Capitated Revenue PMPM: $1,060 in Q4 2025, a 9% increase from $971 in Q4 2024; full year PMPM was $1,026, a 5% increase from $981 in 2024.
Adjusted EBITDA: Q4 loss of $76.1 million compared to a loss of $67.6 million in Q4 2024; full year adjusted EBITDA loss of $161.3 million, an improvement from a loss of $167.2 million in 2024.
Medical Margin: Q4 medical margin was negative $28.7 million; full year medical margin was $23.5 million, down from $85.4 million in 2024.
Operating Expenses: Q4 operating expenses were $35.1 million, up from $28.7 million in Q4 2024; full year operating expenses decreased to $101.8 million from $111.8 million in 2024.
Geographic Expansion: Announced a partnership to enter a new Medicare Advantage geography, adding 29,000 new members, which will contribute approximately $27 million in revenue for 2026.
Provider Network Improvements: Over 50% of patients are now served by Tier 1 provider groups, enhancing clinical integration and accountability.
Quality Performance: Achieved 4-star status across 70% of priority Medicare Advantage plans, which strengthens relationships with payers.
Operational Improvements: Identified $170 million in structural and operational improvements, focusing on contracting, operational execution, and payer collaboration.
2026 Adjusted EBITDA Guidance: Midpoint of $10 million, indicating a potential improvement of up to $170 million from 2025.
At-Risk Membership: Expected to be between 107,000 and 117,000 members, with total revenue projected between $1.5 billion and $1.7 billion.
Revenue Drivers: 75% of the projected improvement is already embedded in contracts, with the remainder dependent on operational initiatives and contract renegotiations.
Continued Losses: Despite improvements, the company reported significant losses in adjusted EBITDA and medical margins.
Operating Expenses Increase: Q4 operating expenses rose due to reclassifications and ongoing costs, indicating potential challenges in cost management.
Dependency on Execution: Future performance is heavily reliant on the successful execution of operational initiatives and contract renegotiations, which may pose risks if not achieved.
Clarification on Membership Numbers: The 112,000 at-risk members do not include the additional 29,000 from the Nebraska agreement.
Glidepath to Risk: The new Nebraska partnership includes a two-year glidepath to risk with performance metrics that must be met.
Contractual Changes: Improved contracts with payers include adjustments based on Stars performance and premium rates, reflecting a more collaborative approach to align incentives. Overall, P3 Health Partners is positioning itself for growth in 2026 with a focus on operational improvements and strategic partnerships, despite facing challenges related to ongoing losses and the need for effective execution of its plans.
SOURCE: Q4 2025 EARNINGS CALL TRANSCRIPT